Valuation: Appili Therapeutics Inc.

Market Cap 1.99M 1.42M 1.24M 1.17M 1.06M 136M 1.99M 13.98M 5.39M 69.15M 5.32M 5.21M 222M P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 14.88M 10.62M 9.26M 8.75M 7.94M 1.02B 14.94M 105M 40.43M 518M 39.91M 39.02M 1.67B EV / Sales 2025
152,429,607x
EV / Sales 2026 60,946,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
08-14 Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-04 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
06-26 Appili Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
02-12 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-18 Appili Therapeutics closes first tranche of non-brokered private placement RE
12-15 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
11-13 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-13 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
11-13 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
11-13 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
11-05 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
1 day+50.00%
1 week+50.00%
1 month+50.00%
6 months-25.00%
Current year-40.00%
1 week 0.01
Extreme 0.01
0.02
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.02
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
1.14
10 years 0.01
Extreme 0.01
1.89
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2022
Director of Finance/CFO 68 15/11/2021
Corporate Officer/Principal - 30/09/2022
Director TitleAgeSince
Chairman 50 06/05/2015
Director/Board Member 58 30/09/2018
Chairman 59 12/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/26 Option

Chief Executive Officer

75,000 0.0584%
01/07/26 Option

Chief Financial Officer

100,000 0.0779%
01/07/26 Option

Director

100,000 0.0779%
Change 5-day change 1-year change 3-year change Capi.($)
+50.00%+50.00%0.00%-72.73% 1.42M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average +4.47%+6.48%+32.37%+179.33% 27.48B
Weighted average by Cap. -0.47%+1.44%+35.38%+147.72%

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.88 0.1 0.71 0.27 3.5 0.27 0.26 11.26 0.24 0.17 0.15 0.14 0.13 16.73 0.25 1.72 0.66 8.5 0.65 0.64 27.36
Net income -2.62M -1.87M -1.63M -1.54M -1.4M -180M -2.64M -18.48M -7.13M -91.41M -7.04M -6.88M -294M -4.24M -3.03M -2.64M -2.49M -2.26M -290M -4.26M -29.86M -11.52M -148M -11.37M -11.12M -475M
Net Debt 11.07M 7.9M 6.89M 6.5M 5.91M 758M 11.11M 77.91M 30.07M 385M 29.67M 29.02M 1.24B 12.9M 9.21M 8.03M 7.58M 6.88M 883M 12.95M 90.8M 35.04M 449M 34.58M 33.81M 1.45B
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
18/09/26 CA$0.0150 +50.00% 1,000
17/09/26 CA$0.0100 0.00% 77,000
16/09/26 CA$0.0100 -33.33% 339,000
15/09/26 CA$0.0150 +50.00% 2,000
  1. Stock Market
  2. Stocks
  3. APLI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!